CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...